{"organizations": [], "uuid": "0c966b67d52549a3bd5cffecb5ccbf36eaf3acb6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-advantagene-announces-clinical-tri/brief-advantagene-announces-clinical-trial-collaboration-idUSASC09Y18", "country": "US", "domain_rank": 408, "title": "BRIEF-Advantagene Announces Clinical Trial Collaboration", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-27T14:20:00.000+03:00", "replies_count": 0, "uuid": "0c966b67d52549a3bd5cffecb5ccbf36eaf3acb6"}, "author": "", "url": "https://www.reuters.com/article/brief-advantagene-announces-clinical-tri/brief-advantagene-announces-clinical-trial-collaboration-idUSASC09Y18", "ord_in_thread": 0, "title": "BRIEF-Advantagene Announces Clinical Trial Collaboration", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-advantagene announces clinical trial collaboration reuters staf", "sentiment": "negative"}, {"name": "bristol", "sentiment": "none"}, {"name": "squibb co", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 22 AM / Updated 8 minutes ago BRIEF-Advantagene Announces Clinical Trial Collaboration Reuters Staff\nApril 27 (Reuters) - Bristol-Myers Squibb Co: * ADVANTAGENE ANNOUNCES CLINICAL TRIAL COLLABORATION\n* ADVANTAGENE INC SAYS COMPANY ENTERED INTO A CLINICAL TRIAL COLLABORATION WITH BRISTOL-MYERS SQUIBB\n* ADVANTAGENE - COLLABORATION TO EVALUATE SAFETY, EFFICACY OF CO’S INVESTIGATIONAL GENE MEDIATED CYTOTOXIC IMMUNOTHERAPY COMBINED WITH BRISTOL’S OPDIVO\n* ADVANTAGENE - ITS INVESTIGATIONAL GMCI COMBINED WITH OPDIVO IS TO TREAT NEWLY DIAGNOSED MALIGNANT GLIOMA PATIENTS GETTING SURGERY WITH/WITHOUT TEMOZOLOMIDE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-04-27T14:20:00.000+03:00", "crawled": "2018-04-27T15:01:23.003+03:00", "highlightTitle": ""}